Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab

Vince B. C. Biemans, C. Janneke van der Woude, Gerard Dijkstra, Andrea E. van der Meulen-de Jong, Bas Oldenburg, Nanne K. de Boer, Mark Loewenberg, Nidhi Srivastava, Alexander G. L. Bodelier, Rachel L. West, Jeroen M. Jansen, Annemarie C. de Vries, Jeoffrey J. L. Haans, Dirk J. de Jong, Marie J. Pierik, Frank Hoentjen*, Dutch Initiative Crohn and Colitis

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1189-1199
Number of pages11
JournalClinical Pharmacology & Therapeutics
Volume107
Issue number5
Early online date11 Dec 2019
DOIs
Publication statusPublished - May 2020

Keywords

  • LONG-TERM EFFECTIVENESS
  • MAINTENANCE THERAPY
  • MULTICENTER COHORT
  • INDUCTION
  • SAFETY
  • IMPACT

Cite this